Protagonist Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary

• Protagonist Therapeutics Inc PTGX.OQ reported a quarterly adjusted loss of 54 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -58 cents. The mean expectation of eight analysts for the quarter was for a loss of 61 cents per share. Wall Street expected results to range from -71 cents to -45 cents per share.

• Revenue was $4.68 million​; analysts expected $2.07 million.

• Protagonist Therapeutics Inc's reported EPS for the quarter was a loss of 54 cents​.

• The company reported a quarterly loss of $33.21 million.

• Protagonist Therapeutics Inc shares had risen by 5.8% this quarter and gained 107.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 3.3% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Protagonist Therapeutics Inc is 52.00

This summary was machine generated from LSEG data November 8 at 04:54 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)